



Putting It All Together: How Safety Data Becomes a Signal

Craig Zinderman, MD, MPH Acting Deputy Director, Division of Epidemiology Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, FDA






Objectives

- Review tools for post-market safety surveillance and signal detection
- Discuss FDA's organizational approach to deciding if a signal is present
- Discuss risk management considerations






Signal Decision Making



Consider the "alert" source: each has strengths and limitations








Signal evaluation: hypothesis testing in a formal pharmacoepidemiologic study





Signal Decision Making




Place the "alert" source in context in order to determine if a safety signal is present





Signal Decision Making

Safety analysis Toolkit Decision: Safety signal



Examine available options and their intended and unintended consequences





Discussion of CBER's signal adjudication process

- Pharmacovigilance and Pharmacoepidemiology, like clinical medicine, are both an art and a science
- An organized process within the Center enhances the acquisition and processing of vaccine safety information by reviewers
- Public health actions are taken after careful consideration by a multidisciplinary team at FDA